<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620382</url>
  </required_header>
  <id_info>
    <org_study_id>201649</org_study_id>
    <secondary_id>1R01HL144568-01A1</secondary_id>
    <nct_id>NCT04620382</nct_id>
  </id_info>
  <brief_title>Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients</brief_title>
  <official_title>Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about the effects of abdominal compression and the&#xD;
      medication midodrine, two interventions used for the treatment of orthostatic hypotension&#xD;
      (low blood pressure on standing), on hemodynamic markers of cardiovascular risk. The study&#xD;
      will be conducted at the Vanderbilt University Medical Center and consists of a screening and&#xD;
      2 testing days, one with abdominal compression and one with midodrine. The total length of&#xD;
      the study will be about 5 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes up to 5 days spent in the Vanderbilt University Medical Center, at least&#xD;
      one day of screening tests, followed by 2 study days.&#xD;
&#xD;
      Screening tests include a physical examination and history, routine safety laboratory&#xD;
      assessments, and testing of the autonomic nervous system. Medications affecting blood&#xD;
      pressure and the autonomic nervous system such as pressor medications will be withdrawn for&#xD;
      at least 5 half-lives before studies, except for fludrocortisone. Other medications will be&#xD;
      held constant throughout the study.&#xD;
&#xD;
      Eligible participants will then be studied on two separate days in random order: one day with&#xD;
      midodrine combined with sham abdominal compression, and one day with abdominal compression&#xD;
      combined with a placebo pill.&#xD;
&#xD;
      On each study day, participants will be instrumented to measure blood pressure, heart rate,&#xD;
      hemodynamic parameters, segmental impedance, and markers of cardiovascular risk. A baseline&#xD;
      tilt table test will be performed to obtain supine and upright baseline measurements,&#xD;
      including the assessment of orthostatic symptoms. Participants will then receive a single&#xD;
      oral dose of placebo or midodrine, and a deflated binder will be placed around the abdomen.&#xD;
      Thirty to sixty minutes later, a second tilt table test will be done with sham or active&#xD;
      abdominal compression. Outcome measurements will be repeated in the supine and upright&#xD;
      positions. At the end of the second tilt table test, the investigators may also assess&#xD;
      splanchnic venous capacitance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, single-blind, crossover</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>placebo pill and sham abdominal compression will be used</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamic markers of cardiovascular risk</measure>
    <time_frame>1 hour post-intervention tilt table test</time_frame>
    <description>augmentation index, central blood pressure, pulse wave velocity</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Neurogenic Orthostatic Hypotension</condition>
  <condition>Autonomic Failure</condition>
  <condition>Pure Autonomic Failure</condition>
  <condition>Multiple System Atrophy</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Midodrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single oral dose of midodrine (5-10mg) combined with sham abdominal compression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abdominal Compression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abdominal compression (up to 40 mmHg) combined with a placebo pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>Midodrine 5-10 mg, single oral dose</description>
    <arm_group_label>Midodrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>single oral dose</description>
    <arm_group_label>Abdominal Compression</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Abdominal compression</intervention_name>
    <description>abdominal compression up to 40 mmHg during head-up tilt</description>
    <arm_group_label>Abdominal Compression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham compression</intervention_name>
    <description>Sham abdominal compression during head-up tilt</description>
    <arm_group_label>Midodrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects, age 40-80 years, with autonomic failure including pure&#xD;
             autonomic failure, multiple system atrophy and Parkinson disease.&#xD;
&#xD;
          -  Neurogenic orthostatic hypotension, defined as a ≥20-mmHg decrease in SBP within 3&#xD;
             minutes of standing associated with impaired autonomic reflexes determined by&#xD;
             autonomic testing in the absence of other identifiable causes.&#xD;
&#xD;
          -  Patients who are willing and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Patients with any contraindication or intolerant to abdominal compression including&#xD;
             history of aortic aneurysms, thoracic, abdominal or pelvic surgery within 6 months of&#xD;
             study participation; symptomatic abdominal or inguinal hernias; severe&#xD;
             gastrointestinal reflux; recent fractures or fissures of ribs, thoracic or lumbar&#xD;
             spine; medical devices implanted on the abdominal wall or abdomen that would interfere&#xD;
             with the abdominal compression.&#xD;
&#xD;
          -  Pre-existing sustained supine hypertension ≥180/110mmHg&#xD;
&#xD;
          -  Bedridden patients or those who are unable to stand due to motor impairment or severe&#xD;
             OH.&#xD;
&#xD;
          -  Patients who cannot tolerate the medication withdrawal, defined as those who are&#xD;
             unable to stand for at least one minute after the medication withdrawal period or&#xD;
             those with sustained supine hypertension ≥180/110mmHg.&#xD;
&#xD;
          -  Clinically unstable coronary artery disease, or major cardiovascular or neurological&#xD;
             event in the past 6 months.&#xD;
&#xD;
          -  Clinically significant pulmonary, renal, hematopoietic, hepatic disease, or other&#xD;
             factors which in the investigator's opinion would prevent the subject from completing&#xD;
             the protocol including clinically significant abnormalities in clinical, mental, or&#xD;
             laboratory testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Okamoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily C Smith, RN</last_name>
    <phone>615-875-1516</phone>
    <email>emily.c.smith@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luis Okamoto, MD</last_name>
    <phone>615-936-6119</phone>
    <email>luis.e.okamoto@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily C Smith, RN BSN MPH</last_name>
      <phone>615-875-1516</phone>
      <email>emily.c.smith@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Luis E Okamoto, MD</last_name>
      <phone>6159366119</phone>
      <email>luis.e.okamoto@vumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Luis E Okamoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andre Diedrich, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfredo Gamboa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyndya A Shibao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily C Smith, RN MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Luis E Okamoto</investigator_full_name>
    <investigator_title>Research Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>midodrine</keyword>
  <keyword>abdominal binder</keyword>
  <keyword>splanchnic circulation</keyword>
  <keyword>arterial stiffness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Pure Autonomic Failure</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT04620382/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

